Q3-FY26 · Ankur
We have started with Stellon Biotech, our US subsidiary, to drive marketing, distribution and commercialization of our products in the US, creating a direct commercial footprint.
CONCORDBIO / language trends
Read confidence between the lines.
Concord Biotech · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q3-FY26 · Ravi Kara
Excluding injectables related startup cost and cost associated with our US subsidiary, EBITDA margins remain in the range of 40% for Q3 and 9M FY26.
Q3-FY26 · Ankur
While FY26 is expected to remain below our historical averages, we anticipate that FY27 and beyond will reflect a normalization in performance.